The COVID-19 pandemic has highlighted more than ever the need for new treatments and drug discovery, which is generally a slow, expensive process that often ends in failure. Martin-Immanuel Bittner argues that previous problems will be overcome by combining robotics and data science, and richer, more reliable data can be generated at speed, enabling better decisions in both human-driven and computational drug discovery.